Navigation Links
Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
Date:6/6/2011

re approximately 475,000 people in the United States alone living with NHL (active disease or in remission).

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has four product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations and beliefs regarding our future results or performance. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" a
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission ... ResMed (RMD) against BMC Medical. In a notice issued on ... found that ResMed,s patent on its humidifier was invalid. ... a "monumental win". "We are very excited with the ITC,s ... position that we have taken since the very beginning on ...
(Date:12/24/2014)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ), the ... Jennifer Hagerman , Pharm.D., AE-C, senior director of ... the president of the Michigan Pharmacists Association on Jan. ... Feb. 28, 2015, at the MPA Annual Convention and ... in Detroit, Michigan . Hagerman will ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3
... Aug. 21 Genetic testing can be,used to ... anticoagulant, according to research published in the,September 1, ... American Society of,Hematology. This result represents one of ... to guide personal medical care., Because individuals ...
... Randomized, Double-Blind Study Targets Biomarker-Defined Population, ... (Nasdaq: GNTA ) announced that the ... confirmatory Phase 3 trial of Genasense,(oblimersen sodium) ... as,AGENDA, is a randomized, double-blind, placebo-controlled study ...
Cached Medicine Technology:Genetics Determine Optimal Drug Dose of Common Anticoagulant 2Genetics Determine Optimal Drug Dose of Common Anticoagulant 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 2Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 5
(Date:12/26/2014)... (PRWEB) December 26, 2014 Yisrayl Hawkins, Pastor ... an open letter in light of the Ferguson, Missouri unrest. ... of civil unrest and explains why it has only increased. ... mankind was even created. He says there is a very ... Yisrayl also says there is a set of rules, or ...
(Date:12/26/2014)... Orlando, FL (PRWEB) December 26, 2014 ... visitor health insurance in the USA, announced today a ... to assist members in choosing the right plan for ... take the complexity out of the selection process when ... premiums by age group with only a few clicks. ...
(Date:12/25/2014)... The microscopy market is estimated to grow ... million by 2019. Optical microscopy is the largest ... product segment is expected to show the fastest ... on nanotechnology, technological advancements, and increasing federal support ... Get Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... 2014 The report “TS-1 (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... an anti-cancer drug which is typically used for treating ... used for treating gastric cancer and pancreatic cancer. TS-1 ... drug was first approved in 1999 in Japan for ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... June 6 The makers of the WaveSense(TM),line of ... the WaveSense Presto and WaveSense KeyNote Pro Blood Glucose,Monitoring ... with premium,features that consumers can buy at a value ... with added features for increased safety., The Presto ...
... University of Cincinnati (UC), says that cases of Amyotrophic ... first Persian Gulf War were caused by certain events ... exposure and illness is not as widespread as previously ... July issue of Neuroepidemiology. , Ronnie Horner, PhD, lead ...
... Carriage Services, Inc.,(NYSE: CSV ) today announced ... which can be found on Carriage,s website at, ... Profile includes updated,discussions of Carriage,s business, operating and ... The Company & Investment Profile is being ...
... part of its,ongoing efforts to alleviate human ... and Development (LIFE), recently shipped an,entire forty-foot ... Somalia., In partnership with California-based RICE ... Agency for the Horn,of Africa (ARAHA), two ...
... Grubb & Ellis,Healthcare REIT, Inc. today announced ... consisting of 22 office condominiums in,the Manchester-suburb of ... Nutfield Professional Center consists of,approximately 70,000 square feet ... Center was renovated in 1990 and again in ...
... 5 joint statement, the,presiding bishops of the Evangelical Lutheran ... citizens to pray for peace in Sudan, and,they called ... there., The Rev. Mark S. Hanson of the ... Church made their comments in a public statement,following a ...
Cached Medicine News:Health News:New WaveSense Presto(TM) and Pro(TM) Glucose Meters to Simplify Testing 2Health News:UC research shows risk of ALS exposure in Gulf War veterans is time limited 2Health News:Carriage Services Updates Company & Investment Profile 2Health News:Grubb & Ellis Healthcare REIT Acquires Nutfield Professional Center in Derry, N.H. 2Health News:Grubb & Ellis Healthcare REIT Acquires Nutfield Professional Center in Derry, N.H. 3Health News:Lutheran, Episcopal Church Presiding Bishops Urge Prayers for Peace in Sudan 2
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... The Vitros ECi brings true ... to immunodiagnostic testing. Highly sensitive assays ... oncology and bone metabolism testing are ... under development. The Vitros ECi can ...
... Vitros 250 is a flexible ... in multiple environments small ... clinics and satellite locations. The ... dilution, and can be automated ...
... In an effort to improve on ... hormones, toxicology, abused drugs, and immunosuppressants ... 1991 which incorporates random access capabilities. ... has undergone several important changes in ...
Medicine Products: